[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bile-duct-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bile-duct-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,69,93,115,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100433876","unity-b-a-prospective-multicentric-single-arm-study-to-evaluate-the-safety-and-efficacy-of-the-unity-b-biodegradable-balloon-expandable-biliary-stent-system-in-subjects-with-biliary-strictures-100433876",false,"NCT04929821","UNITY-B A Prospective, Multicentric, Single-arm Study to Evaluate the Safety and Efficacy of the UNITY-B Biodegradable Balloon-Expandable Biliary Stent System in Subjects With Biliary Strictures","Inclusion Criteria:\n\n* 1\\) A subject with a biliary stricture may be entered into the study with: at least one of the following:\n* Benign fibrotic distal bile duct obstruction\n* Duct occlusion caused by cholelithiasis\n* A benign fibrotic distal obstruction of the Common Bile Duct (CBD), demonstrated by presence of a stenosis on magnetic resonance cholangiopancreatography (MRCP) and\u002For ERCP with proximal ductal dilation and cholestatic liver enzymes levels\n* Ductal anastomotic strictures\n* Malignant Biliary stricture at least 1 cm distal to the hilum as well as periampullary hilar strictures not involving the papilla.\n* Neoplasm diagnosed on clinical and imaging findings\n* Post-ERCP pancreatitis\n* Obstructive jaundice with evidence of pruritus, tea color urine and pale stool\n* Abnormal Bilirubin rate or\n* A planned exchange of plastic stents previously placed for management of symptomatic biliary stricture or\n* A previous Percutaneous Transhepatic Biliary Drainage (PTBD) for management of symptomatic biliary stricture 2) Age ≥ 18 years old\n\nExclusion Criteria:\n\nPatients, male or female, presenting with the following criteria may be included:\n\n1. Subject is unwilling to comply with the follow-up schedule\n2. Life expectancy \\\u003C 12 m,\n3. Inability to pass a guidewire through stricture\n4. Contra-indication for endoscopy or interventional radiology\n5. History of allergic reactions to one of the compounds of investigational product.\n6. Subject is unable or refuses to give informed consent\n7. Subject is pregnant or breastfeeding\n8. Patient under tutorship\n9. Currently participating in another trial before reaching first endpoint.\n10. Pseudo Klatskin tumors (metastases in the liver hilum) and gallbladder carcinoma\n11. Patient need additional biliary stenting with another device than the study device.\n\n    \\-","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"NA","STUDY TYPE: Feasibility study STUDY DESIGN: Prospective, multicenter, single-arm, open-label PRIMARY OBJECTIVE The primary objective is to assess safety of the UNITY Balloon-expandable Biodegradable Biliary Stent System SECONDARY OBJECTIVES Clinical \u002FTechnical \u002FProcedural success, Quality of Life improvement, biodegradation rate",[25,26,27],"Biliary Obstruction","Bile Duct Stricture","Bile Duct Diseases","RECRUITING","2026-06-16",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":32},"2017-10-16",{"date":36,"type":19},"2026-07",{"name":38,"class":39},"QualiMed Innovative Medizinprodukte GmbH","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100492216","gut-microbiome-and-metabolome-in-patients-with-gallstone-disease-after-surgical-and-endoscopic-interventions-100492216","NCT05689255","Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions","A Prospective Cohort Study of Translational Changes in Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions","Inclusion Criteria:\n\n* Aged 21 years to 80 years\n* Diagnosis of symptomatic gallstone disease without or with concomitant bile duct stones based on prior diagnostic radiological imaging such as transabdominal ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS).\n* Will be scheduled for cholecystectomy with or without concomitant ERCP-ES for treatment.\n* Patient is willing to provide informed consent before enrolment in the study.\n\nExclusion Criteria:\n\n* Subjects undergoing ERCP-ES with no intention for future cholecystectomy\n* Use of antibiotics or probiotics within 1 month (exception: use of antibiotics within 48 hours of cholecystectomy or ERCP, as metagenomics will be able to sequence both dead and live bacteria, and marked compositional change is not expected within this time frame)\n* Presence of malignancy diagnosed within the last 1 year\n* Previous gastrectomy, appendicectomy, small bowel or large bowel surgery\n* Inflammatory bowel disease\n* Active gastrointestinal tract infections","21 Years","80 Years",{"count":50,"type":19},65,"OBSERVATIONAL","The goal of this longitudinal observational cohort study is to examine the changes in the composition and diversity of gut microbiome and systemic metabolome in patients with symptomatic gallbladder stones with or without concomitant common bile duct (CBD) stones who will be undergoing cholecystectomy with or without prior endoscopic sphincterotomy (ERCP-ES) and CBD stones extraction. The main questions it aims to answer are whether there are:\n\n* differences in gut microbiome diversity and composition before and after cholecystectomy\n* differences in systemic metabolome before and after cholecystectomy\n* gut microbiome and systemic metabolome changes after cholecystectomy\n\nParticipants will be asked to provide stool, urine, plasma and saliva samples prior to and 1-6 months after cholecystectomy. For patients with concomitant CBD stones who undergo ERCP-ES before cholecystectomy, bile specimens will be collected from the bile duct during ERCP-ES as well as the gallbladder and\u002For during cholecystectomy.",[54,27],"Gallstone Disease",[56,57],"microbiome","metabolome","2026-04-06",{"date":60,"type":32},"2026-04-09",{"date":62,"type":32},"2022-12-23",{"date":64,"type":19},"2026-12-31",{"name":66,"class":67},"Changi General Hospital","OTHER",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":68},"100516902","endoscopic-ultrasound-guided-rendezvous-versus-precut-papillotomy-100516902","NCT06010576","Endoscopic Ultrasound-guided Rendezvous Versus Precut Papillotomy","Endoscopic Ultrasound-guided Rendezvous Technique Versus Early Precut Papillotomy for Difficult Bile Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography: a Multicenter Randomized Controlled Trial","ERVPP","Inclusion Criteria:\n\n* Patients age 18 years or older undergoing ERCP with indication for bile duct cannulation\n* Native major papilla\n* Difficult bile duct cannulation, defined by the presence of 1 of the following: 1) unsuccessful bile duct cannulation within 10 cannulation attempts, 2) unsuccessful bile duct cannulation within 10 minutes spent in cannulation, or 3) 2 unintended pancreatic duct cannulation or opacification with contrast\n* Written informed consent available\n\nExclusion Criteria:\n\n* Unable to provide written informed consent\n* Contraindications for endoscopy due to comorbidities\n* Prior biliary sphincterotomy\n* Surgically altered upper gastrointestinal anatomy or duodenal obstruction precluding a standard ERCP\n* Uncorrectable coagulopathy (INR \\> 1.5) and thrombocytopenia (platelet \\\u003C 50,000) by blood product transfusion\n* Pregnant patients",{"count":78,"type":19},188,[22],"Selective bile duct cannulation is the most important step in endoscopic retrograde cholangiopancreatography (ERCP) for treatment of benign and malignant pancreatobiliary diseases, but it may fail in up to 15% of cases. Precut papillotomy is an advanced ERCP cannulation technique recommended by guidelines for rescue of difficult biliary access, but it is not without limitations. Endoscopic ultrasound (EUS)-guided biliary drainage is a novel interventional EUS technique that has been increasingly performed after failed biliary access by advanced ERCP cannulation techniques.",[27],[83],"ERCP, EUS","2026-02-17",{"date":86,"type":32},"2026-02-19",{"date":88,"type":32},"2023-09-05",{"date":90,"type":19},"2027-06-30",{"name":92,"class":67},"Chinese University of Hong Kong",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":99,"maxAge":48,"enrollmentInfo":100,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":68},"100613167","time-to-post-operative-recovery-of-serum-albumin-as-a-predictor-of-outcome-in-major-hepato-pancreato-biliary-surgeries-100613167","NCT07263061","Time to Post-operative Recovery of Serum Albumin as a Predictor of Outcome in Major Hepato Pancreato Biliary Surgeries","Inclusion Criteria:\n\n1. All patients undergoing major Hepato pancreatico Biliary surgeries.\n2. Patients who are more than 12 years of age\n3. Retrospective arm - Data from 2010\n\nExclusion Criteria:\n\n1. Patients who refuse or are unable to give consent.\n2. Patients with Nephrotic syndrome, Protein losing enteropathies, Inflammatory bowel\n3. Disease, Chronic Liver Disease.\n4. Emergency Surgeries","13 Years",{"count":101,"type":19},1000,"Hepatobiliary and Pancreatic surgery is associated with substantial risk of postoperative complications. Albumin is a negative acute phase protein. Its rapid decline may be due to degree of inflammation due to surgical procedures. The decline may due to multifactorial causes. Currently, contemporary data regarding the time to recovery of albumin, as a marker for early recovery of patient from surgical stress is sparse. Delta albumin is influenced by perioperative fluid administration and albumin supplementation. Delta albumin may not reflect the true surgical stress. Early post op albumin is a reflection of intraoperative events and not postoperative recovery or events and is unpredictable. Shorter recovery time of albumin is associated with less post op complications and hospital stay. Earlier recovery of albumin predicts lower morbidity and shorter hospital stay.",[104,105,27],"Hepatobiliary Disease","Pancreas Disease","2025-12-24",{"date":108,"type":32},"2025-12-31",{"date":110,"type":32},"2025-12-07",{"date":112,"type":19},"2026-10-23",{"name":114,"class":67},"Institute of Liver and Biliary Sciences, India",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":20,"phases":125,"briefSummary":126,"conditions":127,"keywords":136,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":68},"100542265","eus-examination-using-endosound-vision-system-vs-standard-echoendoscope-100542265","NCT06340620","EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope","Randomized Trial of Endoscopic Ultrasound Examination Using EndoSound Vision System vs. Standard Echoendoscope","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing EUS examination for evaluation of the pancreas, bile duct, mediastinal or intraabdominal lymph nodes, or luminal lesions in the esophagus, stomach, duodenum or colon.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Unable to obtain consent for the procedure from either the patient or LAR.\n* Intrauterine pregnancy.","100 Years",{"count":124,"type":19},140,[22],"This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.",[128,129,130,131,27,132,133,134,135],"Pancreatic Disease","Pancreatic Cancer","Pancreatic Cyst","Gastrointestinal Tumor","Bile Duct Cancer","Lymph Node Disease","Submucosal Tumor of Gastrointestinal Tract","Gastrointestinal Cancer",[137,138,139],"Endoscopic ultrasound","EndoSound Vision System","Randomized trial","2024-03-25",{"date":142,"type":32},"2024-04-01",{"date":140,"type":19},{"date":145,"type":19},"2027-12",{"name":147,"class":67},"Orlando Health, Inc.",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":15,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":68},"100405180","results-of-surgical-treatment-of-the-hepatobiliopancreatic-surgical-unit-100405180","NCT04556019","Results of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit","Results of the Surgical Treatment of Patients From Hepatobiliopancreatic Surgical Unit at the Complejo Hospitalario de Navarra","HPB","Inclusion Criteria:\n\n* All patients operated by the HPB Surgical Unit in the last 10 years (retrospective)\n* All patients being operated by the HPB Surgical Unit from January 2019 onwards who provide inform consent (prospective).\n\nExclusion Criteria:\n\n* Patients not eligible for surgery\n* Patients not interested in taking part in the study","15 Years","90 Years",{"count":101,"type":19},"The main aims of this study are:\n\n1. \\- to evaluate post-surgical morbidity and mortality outcomes, following the criteria and the definitions from Claven-Dindo and ISGPS international classifications, of the patients operated by the HPB Surgical Unit.\n2. \\- to evaluate survival and disease-free survival rates of the patients operated by the HPB Surgical Unit due to tumoral cause.",[105,161,162,27],"Liver Diseases","Surgical Procedure, Unspecified",[164],"Hepatobiliopancreatic surgery","2020-09-15",{"date":167,"type":32},"2020-09-21",{"date":169,"type":32},"2019-01-03",{"date":171,"type":19},"2029-01",{"name":173,"class":67},"Fundacion Miguel Servet"]